NCT07230626
Not yet recruiting
Phase 3
A Randomized, Open-Label, Controlled, Multicenter Phase 3 Trial of SYS6002 Versus Chemotherapy of Physician's Choice in Recurrent or Metastatic Cervical Cancer After Platinum-containing Chemotherapy and Anti-PD-(L)1 Agent Therapy
CSPC Megalith Biopharmaceutical Co.,Ltd.0 sites412 target enrollmentStarted: November 20, 2025Last updated:
Overview
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrollment
- 412
- Primary Endpoint
- Overall Survival
Overview
Brief Summary
This study is a randomized, open-label, controlled, multicenter phase Ⅲ clinical trial, which aims to evaluate the efficacy and safety of SYS6002 versus investigator's choice of chemotherapy in the treatment of participants with recurrent or metastatic cervical cancer who have failed platinum-containing chemotherapy and PD-1/L1 inhibitor therapy
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •1\. Patients aged 18-75 years (inclusive);
- •2\. Histologically confirmed recurrent or metastatic cervical cancer (squamous cell, HPV-associated adenocarcinoma, or adenosquamous), not amenable to resection or chemoradiation with curative intent;
- •3\. Subject must have received a platinum-based chemotherapy with anti-PD-(L)1 agent and if was received administered in the adjuvant/neoadjuvant setting subject must have progressed during treatment or within 6 months of treatment completion；received no more than 2 prior systemic therapy in the metastatic/recurrent setting; must have experienced radiographic progression during or after the last treatment regimen;
- •4\. An archival tumor tissue sample or a fresh tissue sample should be provided;
- •5\. Subjects must have measurable disease according to RECIST (version 1.1);
- •6\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •7\. Life expectancy of ≥ 3 months;
- •8\. Major organ function meets the relevant laboratory test standards for hematology, renal function, liver function, and coagulation within 7 days prior to treatment;
- •9.Sexually active fertile subjects must agree to use methods of contraception during the study and at least7 months after termination of study therapy and have a negative urine or serum pregnancy test within 7 days prior to randomization;
- •10.Willing to participate in the study, understand the study procedures, and sign a written informed consent form.
Exclusion Criteria
- •1\. Has other histologies not mentioned as part of the inclusion criteria 2;
- •2\. Active central nervous system metastases or leptomeningeal metastasis;
- •3\. Adverse events from prior antitumor therapy not recovered to ≤ Grade 1 (unless the investigator deems there is no safety risk)；
- •4\. Any serious and/or uncontrolled concurrent illness that may interfere with patient's particiation in the study:
- •Participants with a history of severe cardiovascular disease within 6 months prior to randomization, including but not limited to:
- •Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia and third-degree atrioventricular block requiring clinical intervention; corrected QT interval \> 480 ms by Fridericia method (Fridericia formula: QTcF = QT/RR\^0.33, RR = 60/heart rate); With history of myocardial infarction, unstable angina pectoris, angioplasty and coronary artery bypass surgery; New York Heart Association (NYHA) classification Grade III and above heart failure, and left ventricular ejection fraction (LVEF) \< 50% in the tests and examinations during the screening period; Cerebrovascular Accident; Participants with poorly controlled hypertension on medication, with systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg;
- •Other clinically significant diseases:
- •HbA1c \> 8%; Participants with active keratitis and corneal ulcer, or fundus lesions with a risk of blindness; Grade ≥2 neuropathy prior to randomization; Severe infection within 4 weeks prior to randomization; active infection requiring systemic antibiotics, antiviral, or antifunga therapy within 2 weeks prior to randomization; Active HBV or HCV infection; History of immunodeficiency (HIV-positive, acquired or congenital immunodeficiency, etc.), or organ transplantation; History of another malignancy within 3 years prior to randomization; History of interstitial lung disease (ILD) / non-infectious pneumonia, or current ILD/non-infectious pneumonia, or imaging findings at screening that cannot rule out these condition, except for those who are determined to be risk-free after discussion between the investigator and the sponsor; History of genital tract fistula, except for whose perforations or fistulas that have been treated with resection or repair, and are considered by the investigator to be healed or in remission; Pleural effusion, ascites or pericardial effusion with syptoms or requiring puncture or drainage within 2 weeks prior to randomization;
- •5\. Use of other unmarketed clinical investigational drugs or treatments, chemotherapy, radiotherapy targeted therapy within 4 weeks prior to randomization; use of traditional Chinese medicine with anticancer indication, oral fluoropyrimidine drugs, small molecule targeted drug within 2 weeks prior to randomization; use of palliative radiation or local therapy within 2 weeks prior to randomization;with major surgery within 4 weeks prior to randomization;
- •6\. Allergy to any component of SYS6002, or humanized monoclonal antibodies;
Arms & Interventions
SYS6002
Experimental
SYS6002 monotherapy
Intervention: SYS6002 (Drug)
Chemotherapy
Active Comparator
Investigator's choice of one chemotherapy treatment (topotecan, gemcitabine, pemetrexed, or docetaxel)
Intervention: Investigator's Choice of Chemotherapy (Drug)
Outcomes
Primary Outcomes
Overall Survival
Time Frame: Up to 3.5 years
Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the participant is known to be alive
Secondary Outcomes
- Objective Response Rate (ORR)(Up to 3.5 years)
- Duration of Response (DOR)(Up to 3.5 years)
- Disease Control Rate (DCR)(Up to 3.5 years)
- Progression Free Survival (PFS)(Up to 3.5 years)
- Incidence of adverse events(Up to 3.5 years)
- Incidence of Anti-Drug Antibody (ADA)(Up to 3.5 years)
- Blood concentration of SYS6002(Up to 3.5 years)
Investigators
Similar Trials
Active, not recruiting
Phase 3
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical CancerCervical CancerNCT04906993Jiangsu HengRui Medicine Co., Ltd.443
Recruiting
Phase 3
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCNon-small Cell Lung CancerNCT07183189Suzhou Suncadia Biopharmaceuticals Co., Ltd.576
Recruiting
Phase 3
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveNCT06930794Beijing Pearl Biotechnology Limited Liability Company300
Recruiting
Not Applicable
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerNCT07170995Suzhou Suncadia Biopharmaceuticals Co., Ltd.460
Not yet recruiting
Phase 3
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell CarcinomaNCT06952621Tang-Du Hospital390